中新网长沙12月12日电 (记者 唐小晴)2025年长沙市高价值专利运营大赛(以下简称"长高赛")颁奖仪式12 日在长沙经开区举行。 当前，知识产权已成为国际竞争的核心要素。主办方表示，此次大赛的举办是长沙以赛促创、以赛促转 的生动实践，获奖项目展现了高价值、强运营、重协同的鲜明特点，为湖南专利运营提供了宝贵经验。 (完) 活动现场 的签约仪式。中新网记者 唐小晴 摄 作为长沙市首届聚焦高价值专利运营的专项赛事，长高赛自今年7月启动以来，吸引了企业组、高校院 所组和大学生创新创业组3个竞赛组别共113个项目竞相角逐，覆盖工程机械、人工智能、新材料、新能 源装备、新一代半导体、大健康等战略性新兴产业，充分展示了长沙在关键领域的创新实力与专利转化 成果。 颁奖仪 式。中新网记者 唐小晴 摄 经层层筛选与评审，最终23个项目脱颖而出。其中，湖南国科微电子股份有限公司的"端侧高性能人工 智能融合系列芯片"、湖南大学与湖南极电特能科技有限公司的"钠离子电池高性能硬炭负极材料开 发"、长沙斐视科技有限公司的"超高性能人机共生远程操控机器人系统"三个项目荣膺大赛一等奖。 此外，圣湘生物科技股份有限公司的"呼吸道病原体高效、 ...

Group 1: Industry Trends and Innovations - The "2025 Fifth China Health Industry Development and Rehabilitation Service Conference" was held in Beijing, focusing on integrating resources and exploring development paths in the health industry [1] - The conference featured discussions on cutting-edge topics such as innovative drugs, brain-machine interfaces, AI in healthcare, and the transformation of traditional Chinese medicine [1] - A series of innovative case studies were presented, showcasing advancements in areas like ESG, biotechnology, and AI healthcare, reflecting the vitality and innovation in the health sector [1] Group 2: Company Highlights - Gan Li Pharmaceutical is the first company in China to master the industrial production of recombinant insulin analogs, recently achieving significant milestones with its insulin injection and a commercial agreement for a GLP-1 receptor agonist [2] - Shengxiang Bio focuses on integrated diagnostic and therapeutic solutions, having developed over 1,000 products and served more than 30 billion tests globally, emphasizing its commitment to making life sciences accessible [3] - Nanjing Xinbai has established a dual-driven model in cell therapy and clinical transformation, with significant advancements in immunotherapy for prostate cancer and a leading position in umbilical cord blood storage [4][5] - Mirxes has developed a non-invasive gastric cancer screening solution, filling a technological gap in China and demonstrating significant clinical applicability and commercial potential [9] - Ruixi Bio specializes in micro-ecological medical solutions, having built a comprehensive database and developed a novel theory for precision medical interventions in chronic diseases [12][13]

智通财经APP讯，圣湘生物(688289.SH)发布公告，公司的产品全自动核酸处理系统(S-S13E-P/S-S13E- P1)于近日获得欧盟CEIVDR认证。该设备可实现从样本到报告的全流程自动化，包括样本管开盖、移 液、核酸提取、PCR体系构建、封膜扩增及结果分析，具有处理高效、检测精准、智能控制、广泛兼容 等特点。检测项目丰富，涵盖HPV、性病、血源、呼吸道、虫媒、药物基因组等类别，适配实验室、医 院、检验中心等各类专业应用场景，在有限空间内高效满足样本检测、实验分析等多元化需求。 该款仪器本次获得欧盟CEIVDR认证，标志着公司在分子诊断技术国际化与标准化进程迈出关键一步。 这一里程碑不仅体现了产品的卓越性能与安全标准，更展现了公司引领行业创新、服务全球市场的坚定 承诺。未来，公司将持续推动技术革新与方案融合，赋能全球医疗机构与公共卫生体系，助力构建更高 效、精准、可靠的健康防控新生态。 ...

圣湘生物(688289.SH)发布公告，公司的产品全自动核酸处理系统(S-S13E-P/S-S13E-P1)于近日获得欧盟 CEIVDR认证。该设备可实现从样本到报告的全流程自动化，包括样本管开盖、移液、核酸提取、PCR 体系构建、封膜扩增及结果分析，具有处理高效、检测精准、智能控制、广泛兼容等特点。检测项目丰 富，涵盖HPV、性病、血源、呼吸道、虫媒、药物基因组等类别，适配实验室、医院、检验中心等各类 专业应用场景，在有限空间内高效满足样本检测、实验分析等多元化需求。 该款仪器本次获得欧盟CEIVDR认证，标志着公司在分子诊断技术国际化与标准化进程迈出关键一步。 这一里程碑不仅体现了产品的卓越性能与安全标准，更展现了公司引领行业创新、服务全球市场的坚定 承诺。未来，公司将持续推动技术革新与方案融合，赋能全球医疗机构与公共卫生体系，助力构建更高 效、精准、可靠的健康防控新生态。 ...

该设备可实现从样本到报告的全流程自动化，包括样本管开盖、移液、核酸提取、PCR 体系构建、封 膜扩增及结果分析，具有处理高效、检测精准、智能控制、广泛兼容等特点。检测项目丰富，涵盖 HPV、性病、血源、呼吸道、虫媒、药物基因组等类别，适配实验室、医院、检验中心等各类专业应用 场景，在有限空间内高效满足样本检测、实验分析等多元化需求。 该款仪器本次获得欧盟 CE IVDR 认证，标志着公司在分子诊断技术国际化与标准化进程迈出关键一 步。这一里程碑不仅体现了产品的卓越性能与安全标准，更展现了公司引领行业创新、服务全球市场的 坚定承诺。未来，公司将持续推动技术革新与方案融合，赋能全球医疗机构与公共卫生体系，助力构建 更高效、精准、可靠的健康防控新生态。 格隆汇12月11日丨圣湘生物(688289.SH)公布，公司的产品全自动核酸处理系统(S-S13E-P/S-S13E-P1)于 近日获得欧盟 CE IVDR 认证。 获批主体：圣湘生物科技股份有限公司，证书编号：CMB 1012-2025，预期用途：全自动核酸处理系统 （S-S13E-P/S-S13E-P1）用于临床样本中核酸的提取和纯化，并进行聚合酶链式反应（PC ...

证券代码：688289 证券简称：圣湘生物 公告编号：2025-078 圣湘生物科技股份有限公司 关于自愿披露相关产品获得欧盟 CE 认证的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 圣湘生物科技股份有限公司（以下简称"公司"）的产品全自动核酸处理系统 （S-S13E-P/S-S13E-P1）于近日获得欧盟 CE IVDR 认证，现将相关情况公告如下： | 获批主体 | 圣湘生物科技股份有限公司 | | --- | --- | | 证书编号 | CMB 1012-2025 | | 证书类型 | 欧盟CE IVDR注册证 | | 产品名称 | 英文名称：Fully Automated Nucleic Acid Processing System | | | 中文名称：全自动核酸处理系统 全自动核酸处理系统（S-S13E-P/S-S13E-P1）用于临床样本中核酸的 | | | 提取和纯化，并进行聚合酶链式反应（PCR）扩增、荧光检测以及数 | | 预期用途 | 据分析。适用于血清、血浆、咽拭子、肛拭子、粪便、生殖道 ...

Core Viewpoint - The strategic cooperation agreement between Shengxiang Biotechnology Co., Ltd. and BeiGene (Guangzhou) Innovation Technology Co., Ltd. marks a significant acceleration of Shengxiang's "integrated diagnosis and treatment" strategy [1] Group 1: Cooperation Goals - The collaboration aims to achieve full-link synergy in early screening, precise drug selection, efficacy monitoring, and safety assessment in key areas such as oncology, metabolism, immune inflammation, and children's growth and development [3] - The partnership will leverage large-scale population sample studies to identify suitable intervention targets and optimal timing, enhancing treatment levels in metabolism and immune inflammation while addressing health management challenges related to children's growth and development [3] Group 2: Technological Synergy - The core support for aligning innovative therapies with patient needs lies in precise diagnostic and treatment technologies, which will enhance innovation efficiency and ensure solutions are more aligned with clinical realities [3] - Shengxiang has initiated the construction of an integrated diagnosis and treatment ecosystem, with Shengxiang Haiji serving as the core platform in biopharmaceuticals, facilitating a strong collaboration with BeiGene's innovative research capabilities [3] Group 3: Implementation Framework - The BeiGene Biopharmaceutical Innovation Center will act as the central hub for collaboration, utilizing existing research support, clinical resources, and industrial incubation capabilities to create a comprehensive cooperation chain from technology exploration to clinical validation and practical application [4] - The partnership extends beyond technical collaboration to include joint exploration in children's health and metabolism, as well as coordinated resource layout in the industry, with the potential to expand global cooperation and promote innovative outcomes to more countries and regions [4]

Core Viewpoint - Shengxiang Biotechnology (688289.SH) announced on December 5 that part of the shares held by its major shareholder, Chen Weny, are subject to judicial freezing and enforcement, which will not affect the company's control or daily operations [1][2]. Group 1: Shareholder and Judicial Actions - The shares subject to judicial freezing include 20,720,000 shares, representing 3.58% of the total share capital, which will be adjusted to a "non-restricted sell freeze" status [2]. - The court will allow the applicant to sell up to 4 million shares through the secondary market at a price not lower than 90% of the average price over the previous 30 trading days, with a deadline for the reduction by June 20, 2026 [2]. Group 2: Company Financials and Stock Performance - Shengxiang Biotechnology raised a total of 201.92 million yuan, with a net amount of 186.93 million yuan, exceeding the original plan by 131.27 million yuan [3]. - The company was listed on the Sci-Tech Innovation Board on August 28, 2020, with an initial issuance of 40 million shares at a price of 50.48 yuan per share, and the stock reached a peak of 155.55 yuan on its first trading day [2]. - Currently, the stock is in a state of decline, having fallen below its initial offering price [2].

情绪影响：正面 在中国证券业协会第八次会员大会上，证监会主席吴清发言时提到，适度拓宽券商资本空间与杠杆上 限，提升资本利用效率；对中小机构、外资机构探索差异化监管政策。分析指出，这为券商行业"适度 加杠杆"打开了政策空间，杠杆限制放宽后，券商两融、权益类自营、国际业务及衍生品业务有望直接 受益。 2、险资入市再获松绑！中国股市望迎千亿资金 类型：宏观 情绪影响：正面 12月5日，金融监管总局发布通知，针对保险公司投资的沪深300指数成分股、中证红利低波动100指数 成分股以及科创板股票的风险因子进行调整。专家表示，沪深300指数涵盖了中国股市的核心蓝筹股， 科创板以高科技、高成长性企业为主，符合国家创新驱动战略，释放出"资本松绑"与"长钱长投"的政策 信号。 盘前要闻 1、券商行业迎利好！证监会主席吴清：适度打开资本空间和杠杆限制 类型：行业 3、医保、商保"双目录"发布，19种药品进入商保创新药目录 类型：行业 情绪影响：正面 12月7日，医保、商保"双目录"发布。2025年国家医保药品目录新增114种药品，其中，50种为1类创新 药，19种药品进入商保创新药目录。恒瑞医药、信达生物等多家国内上市公司产品被 ...

Summary of Conference Call Records Industry Overview - The medical device industry is experiencing overall performance pressure in 2025, but third-quarter revenues have shown a year-on-year increase, with a narrowing decline in net profit attributable to the parent company, primarily due to domestic medical insurance cost control and geopolitical influences. It is expected that normal growth rates will resume in 2026 [1][3][8]. Key Points on Medical Device Sector - **Domestic Market Dynamics**: The slowdown in hospital bidding in 2024 is impacting revenue realization, with an expected boost from the "old-for-new" policy by the end of 2025. The In Vitro Diagnostics (IVD) sector is under pressure due to centralized procurement price adjustments and tax reimbursements [1][4]. - **International Market Challenges**: Companies are strengthening their overseas presence, but initial high costs are pressuring short-term profits. The impact of US-China tariffs on low-value consumables is significant, with expectations of price recovery in the glove industry from late 2025 to 2026 after inventory digestion [1][4][11]. - **Performance Metrics**: In the first three quarters of 2025, the medical device sector reported revenues of 145.7 billion yuan, a year-on-year decline of 2.4%, and a net profit of 26.5 billion yuan, down 14.4%. However, the third quarter showed a positive revenue trend and a narrowing profit decline [3][15]. Specific Sector Insights - **IVD Sector**: The IVD sector saw a year-on-year decline of 14.5% in the first three quarters, but the third quarter showed improvement with revenues of 11.02 billion yuan, benefiting from the implementation of centralized procurement and the release of DRG/DIP 2.0 [16]. - **High-Value Consumables**: This segment experienced a revenue growth of 6.6% year-on-year, with orthopedics showing a significant growth rate of 18.7%. The recovery in cardiovascular surgeries is driving sales, and the ophthalmology sector presents potential due to low penetration rates [17]. - **Medical Equipment**: The medical equipment sector's revenue remained flat, but profit growth was slightly higher. The imaging equipment sector is benefiting from the "old-for-new" projects, with a notable recovery in the endoscope segment [15]. Vaccine Sector Performance - The vaccine sector faced significant pressure, with revenues declining nearly 50% and profits turning negative. However, there is a quarter-on-quarter improvement trend. Future focus includes the recovery of traditional vaccines and the launch of new pipeline products, such as the domestically produced nine-valent HPV vaccine [2][23]. Life Sciences Upstream Sector - The life sciences upstream sector's performance remained stable, with a year-on-year profit growth of 68% in the third quarter, driven by recovering terminal demand and improved gross margins. The sector is benefiting from the expansion of the biopharmaceutical market and policy support [24]. Regulatory Environment and Challenges - The current regulatory environment emphasizes innovation while ensuring safety and efficacy. Domestic companies face challenges in international certifications, particularly with the FDA and CE, due to quality control issues [20][21][22]. Future Outlook - The industry outlook for 2026 includes a focus on self-sufficiency, innovative devices, and accelerated realization of centralized procurement categories. The recovery of orthopedic products is already evident, and international expansion remains a key area of interest [5][7][19].